Affirms continued regulatory and industry adoption of biosimulation and technology to bring new drugs to patients PRINCETON, N.J.—Feb. 25, 2021– Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced that 2020 marked the seventh consecutive year where 90% of new drug and biologic approvals by the US Food and Drug Administration (FDA), excluding diagnostic … Continued
Certara University is pleased to announce our complimentary 30-minute Express webinar series: Simplify Your Submission Review Process With an Anywhere, Anytime eCTD Viewer Date/Time: 星期二, 八月 24, 2021 at 11:00AM EST Description: Your organization has numerous stakeholders responsible for reviewing the content of your drug submissions which requires approving eCTD submission content quickly, fielding agency … Continued
PRINCETON, N.J.—Feb. 17, 2021– Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced that it will release preliminary financial results for the fourth quarter and full year of 2020 after the market close on 星期四, 三月 4, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. … Continued
While the pharmaceutical industry in the US and EU has made tremendous progress in pediatric drug development with over 850 products containing pediatric labeling, there is still a significant lag between attaining approval for a drug for adults and the first pediatric label information. Why is this? Conducting pediatric clinical studies has well-known challenges. From … Continued
Abstract During a pandemic caused by a novel pathogen (NP), drug repurposing offers the potential of a rapid treatment response via a repurposed drug (RD) while more targeted treatments are developed. Five steps of model‐informed drug repurposing (MIDR) are discussed: i) utilize RD product label and in vitro NP data to determine initial proof of potential, ii) … Continued
Narratives are an integral part of medical writing. Sponsors sometimes need to prepare large batches of these deliverables in a short period while most traditional methods prove unsuccessful in providing both consistency and quality. This can lead to questions and potential discrepancies in the reporting of a drugs safety. Fortunately, through the advancement and use … Continued
Certara’s COVID-19 vaccine model can be used to investigate dose selection for different populations and determine optimal timing for second vaccine dose PRINCETON, N.J.—2021 年 2 月 5 日. Certara, the global leader in biosimulation, today announced that it has published a white paper on how biosimulation can be used to optimize the world’s limited supply of COVID-19 … Continued
PRINCETON, NJ.— 2020 年 12 月 10 日 – Certara, Inc. (“Certara”), a global leader in biosimulation, today announced the pricing of its upsized initial public offering of 29,055,000 shares of its common stock at $23.00 per share. Certara is offering 14,630,000 shares of its common stock and certain selling stockholders are offering 14,425,000 shares of common stock … Continued
The Pharmacy department of the Shanghai Chest Hospital is dedicated to developing and applying model-informed precision dosing (MIPD) and model-informed drug development (MIDD) models to optimize dosing for patients in China. Certara has partnered with Professor Jiao for 20 years to provide academic training to graduate students and researchers on using its pharmacometric software, including … Continued
